Natural Capsules Limited

BSE: 524654 NSE: NATCAPSUQ
Natural Capsules Limited - pharma in Bengaluru, Karnataka, India. FY 2026 financials & compliance.
CIN L85110KA1993PLC014742 Incorporated 20 September 1993 ROC Bangalore HQ Bengaluru, Karnataka, India
Active Listed - NSE: NATCAPSUQ · BSE: 524654 Public Limited Company pharma
Data last updated
Market Cap
₹149 Cr
NATCAPSUQ · NSE
Share Price
₹147.10
+3.00% today
Revenue
₹187 Cr
FY 2025-26 · +10.6% YoY
EBITDA
−₹0.89 Cr
Margin -0.5%
Net Profit
−₹17.07 Cr
FY 2025-26 · -4164.3% YoY
ROE
-13.7%
ROCE -4.8%
Debt / Equity
0.49
Interest cover -64.5x
Authorised capital
₹15 Cr
Registered with MCA

About Natural Capsules Limited

Data last updated:

Natural Capsules Limited is a public limited company based in Bengaluru, Karnataka, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 20 September 1993 and has been in existence for over 33 years.

The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN L85110KA1993PLC014742. It is a listed company as per MCA records. Its shares are listed on BSE: 524654 and NSE: NATCAPSUQ.

The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹10.41 Cr. It is led by directors including Sunil Laxminarayana Mundra (Managing Director) and Laxminarayan Moondra (Whole-Time Director).

Its last annual general meeting (AGM) was held on 04 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Trident Towers 4th Floor (Level 3) No. 23 100 Feet Road Jaynagar II Block, Bengaluru, Karnataka, India – 560011.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹187.2 Cr, a growth of 10.6% compared to the previous year. For the same year it recorded a net loss of ₹17.07 Cr (net margin -9.1%) and EBITDA of -₹89 Lakh (EBITDA margin -0.5%). The net worth stands at ₹221.63 Cr (down 4.9% YoY). Total assets are valued at ₹351.46 Cr (down 3.1% YoY).

The company has about 172 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand: Natural Capsules. As per MCA filings, the company has open charges of ₹154.08 Cr and satisfied charges of ₹12.5 Cr on record. Court records list 42 cases involving the company, including 33 filed by the company and 9 filed against it; 8 cases are pending. The company has 57 deals on record (42 market trades, 11 secondary share transfers, 3 funding rounds), with disclosed funding of ₹10.28 Cr; the latest was in August 2026. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Stanford Laboratories Private Ltd with revenue of ₹178.12 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2022, listing 1 overdue payment to 1 micro and small supplier.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website naturalcapsules.com.

Company details

CIN L85110KA1993PLC014742
Registration Number 014742
Incorporation Date 20 September 1993
ROC Bangalore
Listing Status Listed - Listed on NSE (NATCAPSUQ); Listed on BSE (524654)
Company Status Active
Date of Last AGM 04 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Natural Capsules has one previous CIN (Corporate Identification Number): U85110KA1993PTC014742. The current CIN is L85110KA1993PLC014742, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L85110KA1993PLC014742Current
U85110KA1993PTC014742Previous
Key People
Sunil Laxminarayana Mundra Managing Director Laxminarayan Moondra Whole-Time Director Sathyanarayana Mundra Whole-Time Director

Contact details

Natural Capsules Limited's registered office is in Bengaluru, Karnataka. Its website is naturalcapsules.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    naturalcapsules.com
  • Social Media
  • Registered Address
    Trident Towers 4th Floor (Level 3) No. 23 100 Feet Road Jaynagar II Block, Bengaluru, Karnataka, India – 560011
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Natural Capsules Limited, buy the company report.

Comprehensive company report
Natural Capsules Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Natural Capsules operates one associated brand: Natural Capsules. Each brand links to its own profile.

BrandDescriptionWebsite
Natural Capsules
Manufacturing and supply chain services for biopharma sector are provided.naturalcapsules.com

Business activity

The main business activity of Natural Capsules is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Natural Capsules Limited, buy the company report.

Financials of Natural Capsules Limited

FY 2025-26 filings available

Natural Capsules Limited reported revenue of ₹187.2 Cr (up 10.6% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹187 Cr
+10.6% YoY
EBITDA
−₹0.89 Cr
-105.0% YoY
Profit After Tax
−₹17.07 Cr
-4164.3% YoY
Net Worth
₹222 Cr
-4.9% YoY
Total Assets
₹351 Cr
-3.1% YoY
Total Debt
₹115 Cr
+9.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue18716915517213579.5161.55
Revenue growth+10.6%+8.9%-9.8%+27.6%+69.9%+29.2%-
EBITDA(0.89)17.7520.0635.3725.5011.105.44
EBITDA margin-0.5%+10.5%+12.9%+20.5%+18.9%+14.0%+8.8%
Profit before tax(27.92)2.798.0625.0019.399.161.36
Net profit(17.07)0.425.5618.4213.875.270.84
Net profit margin-9.1%+0.3%+3.6%+10.7%+10.3%+6.6%+1.4%
EPS (₹)(16.44)0.415.9519.8919.8411.091.38
Balance sheet
Total assets35136333824513671.8562.03
Net worth22223320412382.9862.0955.62
Total debt11510510996.8052.789.636.26
Cash & bank4.825.2813.346.924.882.180.93
Net working capital64.1077.3688.3660.7148.8217.7125.99
Cash flow
Cash from operations10.9226.75(8.35)17.22(0.52)12.607.20
Cash from investing(10.77)(44.48)(72.59)(105)(45.87)(15.58)(5.74)
Cash from financing(0.62)16.1781.7287.4947.702.75(1.19)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue48.7158.4537.7545.8045.2044.9743.8341.22
Revenue growth (YoY)+7.8%+30.0%-13.9%+11.1%+15.4%---
Other income2.350.760.450.160.360.300.110.11
EBITDA1.121.33(2.32)(0.89)0.324.384.274.50
EBITDA margin+2.3%+2.3%-6.1%-1.9%+0.7%+9.7%+9.7%+10.9%
Depreciation4.334.284.364.294.212.162.332.35
Interest4.972.892.852.682.531.641.541.65
Profit before tax(5.83)(5.08)(9.08)(7.70)(6.06)0.880.510.61
Tax(0.09)(0.10)(1.97)(0.70)(0.49)0.370.401.23
Net profit(5.74)(4.98)(7.11)(7.00)(5.57)0.510.11(0.62)
EPS (₹)(5.54)(4.80)(6.88)(6.76)(5.40)0.130.10(0.60)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue17416815417313579.5161.55
Revenue growth+3.5%+9.2%-11.0%+28.0%+69.9%+29.2%-
EBITDA21.8019.4820.9035.7625.6211.135.44
EBITDA margin+12.6%+11.6%+13.6%+20.7%+19.0%+14.0%+8.8%
Profit before tax15.069.3010.3925.7519.439.181.36
Net profit11.216.717.8019.1713.915.290.84
Net profit margin+6.5%+4.0%+5.1%+11.1%+10.3%+6.7%+1.4%
EPS (₹)10.806.498.3620.7019.9011.151.38
Balance sheet
Total assets24022319417411672.5462.03
Net worth18016613212483.0562.1355.62
Total debt59.2656.4061.9649.4233.2810.296.26
Cash & bank2.252.719.252.252.990.230.93
Net working capital40.4256.6957.2040.6432.0233.2025.98
Cash flow
Cash from operations36.1618.035.4020.105.095.787.20
Cash from investing(33.76)(34.37)(10.84)(55.42)(30.42)(8.54)(5.74)
Cash from financing(2.85)14.817.2334.4526.512.52(1.19)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue43.0250.8034.1544.5844.2444.3643.4141.03
Revenue growth (YoY)-2.8%+14.5%-21.3%+8.7%+13.0%---
Other income2.312.132.111.731.691.551.150.77
Total expenses36.1341.9532.2539.1439.1139.3138.8336.09
EBITDA6.898.851.905.445.135.054.584.94
EBITDA margin+16.0%+17.4%+5.6%+12.2%+11.6%+11.4%+10.6%+12.0%
Depreciation2.102.062.092.021.991.942.142.16
Interest1.441.491.451.451.361.521.391.54
Profit before tax5.667.430.473.703.473.142.202.01
Tax1.621.910.090.890.950.510.511.09

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue48.7158.4537.7545.8045.2044.9743.8341.22
Revenue growth (YoY)+7.8%+30.0%-13.9%+11.1%+15.4%---
Other income2.350.760.450.160.360.300.110.11
EBITDA1.121.33(2.32)(0.89)0.324.384.274.50
EBITDA margin+2.3%+2.3%-6.1%-1.9%+0.7%+9.7%+9.7%+10.9%
Depreciation4.334.284.364.294.212.162.332.35
Interest4.972.892.852.682.531.641.541.65
Profit before tax(5.83)(5.08)(9.08)(7.70)(6.06)0.880.510.61
Tax(0.09)(0.10)(1.97)(0.70)(0.49)0.370.401.23
Net profit(5.74)(4.98)(7.11)(7.00)(5.57)0.510.11(0.62)
EPS (₹)(5.54)(4.80)(6.88)(6.76)(5.40)0.130.10(0.60)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue18716915517213579.5161.55
Revenue growth+10.6%+8.9%-9.8%+27.6%+69.9%+29.2%-
Other income1.730.701.940.571.012.910.95
Total expenses18815113513711068.4156.11
Employee cost19.4712.6711.009.518.486.975.91
EBITDA(0.89)17.7520.0635.3725.5011.105.44
EBITDA margin-0.5%+10.5%+12.9%+20.5%+18.9%+14.0%+8.8%
Depreciation17.149.128.677.215.044.314.12
Interest11.626.545.273.732.080.540.91
Profit before tax(27.92)2.798.0625.0019.399.161.36
Tax(3.26)2.182.506.555.472.240.52
Net profit(17.07)0.425.5618.4213.875.270.84
Net profit margin-9.1%+0.3%+3.6%+10.7%+10.3%+6.6%+1.4%
EPS (₹)(16.44)0.415.9519.8919.8411.091.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital57.0557.019.339.287.016.236.23
Reserves & surplus16517619411475.9755.8649.39
Shareholders' funds (net worth)22223320412382.9862.0955.62
Minority interest13.0924.2225.0025.020.000.000.00
Secured loans44.9736.9530.0222.0516.279.636.26
Unsecured loans70.5068.2578.9974.7536.510.000.00
Total debt11510510996.8052.789.636.26
Total liabilities35136333824513671.8562.03
Assets
Gross block36235416414911286.8969.61
Net block27428410396.7766.4938.1123.81
Capital work in progress3.700.0014487.7020.116.982.11
Investments2.732.732.730.000.040.005.57
Inventories26.3325.4619.049.795.528.406.86
Sundry debtors71.3562.2454.4752.1326.3026.7030.36
Cash & bank balances4.825.2813.346.924.882.180.93
Loans & advances34.3036.6036.9233.6139.826.451.14
Total current assets13713012410276.5243.7339.29
Total current liabilities72.7052.2235.4141.7427.7026.0213.30
Net working capital64.1077.3688.3660.7148.8217.7125.99
Total assets35136333824513671.8562.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.692.251.481.400.100.330.06
Net cash from operating activities10.9226.75(8.35)17.22(0.52)12.607.20
Net cash from investing activities(10.77)(44.48)(72.59)(105)(45.87)(15.58)(5.74)
Net cash from financing activities(0.62)16.1781.7287.4947.702.75(1.19)
Net change in cash(0.47)(1.57)0.780.081.30(0.23)0.27
Closing cash4.825.2813.346.924.882.180.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.6%+8.9%-9.8%+27.6%+69.9%+29.2%-
EBITDA growth-105.0%-11.5%-43.3%+38.7%+129.7%+104.0%-
PBT growth--65.4%-67.8%+28.9%+111.7%+573.5%-34.3%
Net income growth-4164.3%-92.5%-69.8%+32.8%+163.2%+527.4%-
Revenue CAGR (3Y)+2.8%+7.8%+25.0%+41.0%+31.2%+13.2%-
EBITDA CAGR (3Y)--11.4%+21.8%+86.6%+76.2%+26.1%-
Profitability & leverage
Net income margin-13.2%+0.4%+3.6%+10.7%+10.3%+8.7%+1.4%
Return on capital employed-4.8%+2.9%+5.0%+16.1%+20.6%+11.2%+3.7%
Return on net worth-13.7%+0.3%+3.4%+17.9%+19.2%+8.9%+1.6%
Debt / equity0.490.490.630.730.430.140.11
Long-term debt / equity0.250.290.420.510.240.000.00
Interest cover-64.4575.7846.2713.2510.177.9568.94
Efficiency & per share
Fixed asset turnover0.520.650.991.321.361.020.91
Inventory turnover7.237.6010.7822.5219.4110.429.34
Debtors turnover2.802.902.924.405.102.791.97
EPS (₹)(16.44)0.415.9519.8919.8411.091.38
Dividend per share (₹)0.000.000.001.001.001.000.60
Book value per share (₹)168.46180.12218.39132.85118.3499.6389.24
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue43.0250.8034.1544.5844.2444.3643.4141.03
Revenue growth (YoY)-2.8%+14.5%-21.3%+8.7%+13.0%---
Other income2.312.132.111.731.691.551.150.77
Total expenses36.1341.9532.2539.1439.1139.3138.8336.09
EBITDA6.898.851.905.445.135.054.584.94
EBITDA margin+16.0%+17.4%+5.6%+12.2%+11.6%+11.4%+10.6%+12.0%
Depreciation2.102.062.092.021.991.942.142.16
Interest1.441.491.451.451.361.521.391.54
Profit before tax5.667.430.473.703.473.142.202.01
Tax1.621.910.090.890.950.510.511.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue17416815417313579.5161.55
Revenue growth+3.5%+9.2%-11.0%+28.0%+69.9%+29.2%-
Other income7.654.243.151.070.932.900.95
Total expenses15214813313710968.3856.11
Employee cost13.7512.2910.959.518.486.975.91
EBITDA21.8019.4820.9035.7625.6211.135.44
EBITDA margin+12.6%+11.6%+13.6%+20.7%+19.0%+14.0%+8.8%
Depreciation8.168.338.577.205.044.314.12
Interest6.236.095.093.882.080.540.91
Profit before tax15.069.3010.3925.7519.439.181.36
Tax3.852.592.596.555.472.240.52
Net profit11.216.717.8019.1713.915.290.84
Net profit margin+6.5%+4.0%+5.1%+11.1%+10.3%+6.7%+1.4%
EPS (₹)10.806.498.3620.7019.9011.151.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.3910.349.339.287.016.236.23
Reserves & surplus16915612311576.0455.9049.39
Shareholders' funds (net worth)18016613212483.0562.1355.62
Secured loans58.1255.0161.9549.1616.279.636.26
Unsecured loans1.141.390.010.2617.010.660.00
Total debt59.2656.4061.9649.4233.2810.296.26
Total liabilities24022319417411672.5462.03
Assets
Gross block16315615214610883.4069.61
Net block87.7588.1690.5193.2262.9434.5923.81
Capital work in progress1.910.002.120.001.073.452.11
Investments22.7422.7422.7420.010.050.025.58
Inventories20.3021.1117.519.305.528.406.86
Sundry debtors61.2863.0253.5652.1326.3026.7030.36
Cash & bank balances2.252.719.252.252.990.230.93
Loans & advances7.6211.4810.9211.9123.5522.821.13
Total current assets91.4598.3291.2475.5958.3658.1539.28
Total current liabilities51.0341.6334.0434.9526.3424.9513.30
Net working capital40.4256.6957.2040.6432.0233.2025.98
Total assets24022319417411672.5462.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.672.190.401.280.090.330.06
Net cash from operating activities36.1618.035.4020.105.095.787.20
Net cash from investing activities(33.76)(34.37)(10.84)(55.42)(30.42)(8.54)(5.74)
Net cash from financing activities(2.85)14.817.2334.4526.512.52(1.19)
Net change in cash(0.45)(1.53)1.79(0.87)1.18(0.24)0.27
Closing cash2.252.719.252.252.990.230.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.5%+9.2%-11.0%+28.0%+69.9%+29.2%-
EBITDA growth+11.9%-6.8%-41.6%+39.6%+130.2%+104.6%-
PBT growth+61.9%-10.5%-59.7%+32.5%+111.7%+575.0%-34.3%
Net income growth+67.1%-14.0%-59.3%+37.8%+163.0%+529.8%-
Revenue CAGR (3Y)+0.2%+7.5%+24.6%+41.1%+31.2%+13.2%+4.7%
EBITDA CAGR (3Y)-15.2%-8.7%+23.4%+87.3%+76.5%+26.2%+6.1%
Profitability & leverage
Net income margin+6.5%+4.0%+5.1%+11.1%+10.3%+8.7%+1.4%
Return on capital employed+9.2%+7.4%+8.4%+20.4%+22.8%+11.2%+3.7%
Return on net worth+6.5%+4.5%+6.1%+18.5%+19.2%+9.0%+1.6%
Debt / equity0.330.400.440.400.300.140.11
Long-term debt / equity0.120.160.190.190.110.000.00
Interest cover45.6754.6241.2813.5910.117.9268.94
Efficiency & per share
Fixed asset turnover1.091.091.031.361.411.040.91
Inventory turnover8.398.7011.4723.3319.4110.429.34
Debtors turnover2.802.882.914.415.102.791.97
EPS (₹)10.806.498.3620.7019.9011.151.38
Dividend per share (₹)0.000.000.001.001.001.000.60
Book value per share (₹)173.03160.83141.30133.74118.4599.6889.24

To see the full year-wise statements and ratios of Natural Capsules Limited, buy the company report.

Board of directors of Natural Capsules Limited

Natural Capsules has 8 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Laxminarayan Moondra
Also directs: Mavion Pharmasciences Private Limited, Natural Biogenex Private Limited, Tajos Investments Private Limited and 1 more
Whole-Time Director01 Jun 201115 Years 4 MonthsCurrent
Jyoti Mundra
Also directs: Nandi Synthetics Private Limited
Director30 Mar 201511 Years 6 MonthsCurrent
Pramod Kasat
Also directs: Natural Biogenex Private Limited, Advanced Enzyme Technologies Limited, Sai Silks (Kalamandir) Limited and 5 more
Director30 May 20197 Years 4 MonthsCurrent
Sushil Kumar Mundra
Also directs: Mavion Pharmasciences Private Limited, Square Plus Life Sciences Private Limited, Natural Phyto Pharma Private Limited and 1 more
Director20 Sep 199333 Years 1 MonthsCurrent
Sunil Laxminarayana Mundra
Also directs: Natural Biogenex Private Limited, Tajos Investments Private Limited, Square Plus Life Sciences Private Limited and 1 more
Managing Director01 Jun 201115 Years 4 MonthsCurrent
Sathyanarayana Mundra
Also directs: Square Plus Life Sciences Private Limited, Nandi Synthetics Private Limited
Whole-Time Director20 Sep 199333 Years 1 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Natural Capsules Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Natural Capsules Limitedthis company₹187.2 Cr (FY 2026)-₹17.07 Cr-9.1%10.6%172Bengaluru, Karnataka, India
Stanford Laboratories Private Ltd₹178.12 Cr (FY 2025)3.0%New Delhi, Delhi, India
BDR Lifesciences Private Limited₹176.87 Cr (FY 2025)-5.0%Vadodara, Gujarat, India
Bakson Drugs and Pharmaceuticals Private Limited₹172.81 Cr (FY 2025)15.0%New Delhi, Delhi, India
Shree Krishnakeshav Laboratories Limited₹170.52 Cr (FY 2025)13.0%Ahmedabad, Gujarat, India
Stericon Pharma Private Limited₹169.15 Cr (FY 2025)21.0%Bangalore, Karnataka, India
Eurolife Healthcare Private Limited₹168.9 Cr (FY 2020)-20.0%Thane, Maharashtra, India
Medicamen Biotech Limited₹168.79 Cr (FY 2025)-7.0%New Delhi, Delhi, India
Group Pharmaceuticals Limited₹168.31 Cr (FY 2025)10.0%Thane, Maharashtra, India

To see the full peer comparison of Natural Capsules Limited, buy the company report.

Auditor

Natural Capsules Limited is audited by P Chandrasekar LLP for the financial year 2023.

Auditor firmFinancial yearFirm registration number
P Chandrasekar LLPFY 2023000580S/S200066

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 50.90%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 49.10%.

Promoters: 50.90%Retail & Others: 49.10%
Sep 2026
QUARTER
50.90% Promoters
49.10% Retail & Others
Promoter holding - history
Now 50.90% · Sep 2026High 51.30% · Dec 2025Low 50.90% · Sep 2026
49%50%51%52%53%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 51.30%Mar 2026: 51.30%Jun 2026: 51.00%Sep 2026: 50.90%51.30%50.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters50.90%51.00%51.30%51.30%
Public49.10%49.00%48.70%48.70%

Charges & borrowings

Open charges
₹154.08 Cr
Satisfied charges
₹12.5 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹79.11 Cr
State Bank of India₹68.10 Cr
Others₹6.87 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
09 Jun 2026101311827Hdfc Bank Limited₹3 CrOpen
30 Jul 2025101147575Others₹5 CrOpen
06 Apr 2022100571390State Bank of India₹40 CrOpen
27 Oct 2021100505041Hdfc Bank Limited₹40 CrOpen
11 Oct 2021100499019Hdfc Bank Limited₹36.11 CrOpen

To see the full charge records of Natural Capsules Limited, buy the company report.

Total charge records: 8 View all charges

Deals & funding

Natural Capsules Limited has 57 deals on record (42 market trades, 11 secondary share transfers, 3 funding rounds), with disclosed funding of ₹10.28 Cr; the latest was in August 2026.

Total deals
57
Market trades
42
Secondary share transfers
11
Funding rounds
3
Rights issue
1
Disclosed funding
₹10.28 Cr

Deals on record (5 of 57)

WhenDealAmountParties
Aug 2026Market trade₹1.12 CrSeller: Tarinika Management LLP
Mar 2026Market trade₹5.53 CrBuyer: Tarinika Management LLP
Seller: an individual
Mar 2026Market trade₹4.9 CrBuyer: an individual
Seller: Tarinika Management LLP
Sep 2025Market trade₹1.89 CrBuyer: Bytes and Pixels Finsoft LLP
Seller: Bytes and Pixels Finsoft LLP
Sep 2025Market trade₹2.64 CrBuyer: Bytes and Pixels Finsoft LLP
Seller: Bytes and Pixels Finsoft LLP

To see the full deal history of Natural Capsules Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Natural Capsules Limited was last rated by Care on 01 Sep 2022.

Rating agencyRated onRating
Care01 Sep 2022

To see the full credit ratings and regulatory alerts of Natural Capsules Limited, buy the company report.

MSME payment delays

Natural Capsules Limited has 1 MSME Form 1 return on record for the period ending Mar 2022, listing 1 overdue payment to 1 micro and small supplier. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (1 of 1)

SupplierAmount dueDue sinceReported on
Quadsun Solar Private Limited

To see the full MSME payment records of Natural Capsules Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Natural Capsules has 2 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

2
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Natural Biogenex Private LimitedU24239KA2020PTC137602
Natural Phyto Pharma Private LimitedU73200KA2018PTC117070

To see the full group structure of Natural Capsules Limited, buy the company report.

Employees & EPFO

Natural Capsules Limited has a workforce of 172 employees on its EPFO records as of Apr 06, 2024, across 2 active EPFO establishments.

Employee count
172
Active EPFO establishments
2
Employee growth
4.88%

GST

No GST registration is on our record for Natural Capsules Limited; the GSTIN and return-filing check is in the company report Buy the company report.

Recent activity

Natural Capsules Limited has 24 board changes on record since 1993: 16 appointments and 8 cessations. The latest: Rangachar Padmanabhan Cattan Coletore ceased to be Director on 24 Aug 2024.

Charges
A charge with Hdfc Bank Limited amounted to Rs. 3.00 Cr with Charge ID 101311827 was registered on 09 Jun 2026.
Filing
Natural Capsules Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Bangalore.
Charges
A charge with State Bank Of India of Rs. 28.10 Cr registered on 24 Nov 1994 with Charge ID 80002092 was modified on 27 Feb 2026.
AGM
Natural Capsules Limited last Annual general meeting of members was held on 04 Aug 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 5.00 Cr with Charge ID 101147575 was registered on 30 Jul 2025.
Charges
A charge with Hdfc Bank Limited of Rs. 40.00 Cr registered on 27 Oct 2021 with Charge ID 100505041 was modified on 25 Jul 2025.
Charges
A charge with Hdfc Bank Limited of Rs. 36.11 Cr registered on 11 Oct 2021 with Charge ID 100499019 was modified on 25 Jul 2025.
Charges
A charge with State Bank Of India of Rs. 40.00 Cr registered on 06 Apr 2022 with Charge ID 100571390 was modified on 13 Jun 2025.
Charges
A charge registered on 20 Nov 2023 via Charge ID 100828649 with Others was fully satisfied on 09 Apr 2025.
Ceased
Rangachar Padmanabhan Cattan Coletore ceased to be Director.
Appointed
Tekkar Yashwanth Prabhu was appointed as Director.
Charges
A charge with Others amounted to Rs. 12.50 Cr with Charge ID 100828649 was registered on 20 Nov 2023.

28 earlier events are in the company report.

News

Frequently asked questions

Natural Capsules is an active public limited company based in Bengaluru, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 20 September 1993 (33+ years old) and is registered under CIN L85110KA1993PLC014742. Listed on BSE: 524654 and NSE: NATCAPSUQ.

Natural Capsules reported revenue of ₹187.2 Cr for FY 2025-26 (up 10.6% YoY) based on consolidated financials.

Natural Capsules has 8 current directors:

The latest financial statements of Natural Capsules on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 04 August 2025. Year-wise statements from 2015 are in the company report.

The CIN (Corporate Identification Number) of Natural Capsules is L85110KA1993PLC014742. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Natural Capsules is a listed company as per MCA records. Its shares are listed on both BSE (code: 524654) and NSE (symbol: NATCAPSUQ).

Natural Capsules has 42 court cases on record: 33 filed by the company and 9 filed against it. 8 are pending. Most are in the district courts.

Natural Capsules was incorporated on 20 September 1993, making it 33+ years old. It is registered with the Registrar of Companies, Bangalore.

Natural Capsules has 57 deals on record (42 market trades, 11 secondary share transfers, 3 funding rounds), with disclosed funding of ₹10.28 Cr; the latest was in August 2026.

The peers of Natural Capsules by revenue are Stanford Laboratories Private Ltd, BDR Lifesciences Private Limited, Bakson Drugs and Pharmaceuticals Private Limited, Shree Krishnakeshav Laboratories Limited, Stericon Pharma Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Rangachar Padmanabhan Cattan Coletore ceased to be Director on 24 Aug 2024. Tekkar Yashwanth Prabhu was appointed as Director on 19 Jun 2024. Anjan Kumar Roy ceased to be Director on 10 Aug 2022. Natural Capsules has 24 board changes on record in total.

Natural Capsules has 1 MSME Form 1 return on record for the period ending Mar 2022, listing 1 overdue payment to 1 micro and small supplier. The latest return was filed on 30 Apr 2022.